Short Interest in WuXi AppTec Co., Ltd. (OTCMKTS:WUXIF) Increases By 51.4% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY – Get Free Report) saw a large increase in short interest in May. As of May 15th, there was short interest totalling 10,600 shares, an increase of 221.2% from the April 30th total of 3,300 shares. Based on an average daily volume of 9,100 shares, the short-interest ratio is presently […]
Hong Kong stocks rise
further on Friday, as market sentiment continued to improve,
buoyed by China s stepped-up efforts to boost the economy. The Hang Seng Index climbed 1.1% by midday,. -May 03, 2024 at 12:58 am EDT
- MarketScreener
China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd.
China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd.